S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

Aeglea BioTherapeutics Insider Trades

-0.14 (-3.85%)
(As of 12/8/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
920,824 shs
Average Volume
198,481 shs
Market Capitalization
$172.62 million
P/E Ratio
Dividend Yield

Aeglea BioTherapeutics (NASDAQ:AGLE) Insider Buying and Selling Activity

Insider Ownership

Number Of
Insiders Buying
(Last 12 Months)

Amount Of
Insider Buying
(Last 12 Months)
$110.68 K

Number Of
Insiders Selling
(Last 12 Months)

Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Get AGLE Insider Trade Alerts

Want to know when executives and insiders are buying or selling Aeglea BioTherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Aeglea BioTherapeutics (NASDAQ AGLE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2021Jonathan AlspaughCFOBuy7,200$6.72$48,384.00  
8/16/2021Jonathan AlspaughCFOBuy9,780$6.37$62,298.60  
4/30/2020Anthony G. QuinnCEOBuy165,000$4.75$783,750.00  
6/14/2019Anthony G QuinnCEOBuy31,905$6.16$196,534.80333,955  
6/12/2019Anthony G QuinnCEOBuy12,217$6.11$74,645.87333,955  
5/22/2019Anthony G QuinnCEOBuy26,592$6.77$180,027.84304,135  
5/20/2019Anthony G QuinnCEOBuy8,989$6.56$58,967.84304,135  
5/17/2019Anthony G QuinnCEOBuy6,218$6.65$41,349.70277,152  
5/15/2019Anthony G QuinnCEOBuy6,256$6.76$42,290.56277,152  
2/15/2019Anthony G QuinnCEOBuy719$7.10$5,104.90277,152  
9/27/2018Aaron SchuchartInsiderSell6,000$9.50$57,000.008,400  
5/10/2018Bioventures Ltd NovartisMajor ShareholderSell73,955$10.12$748,424.60  
5/7/2018Bioventures Ltd NovartisMajor ShareholderSell15,548$10.11$157,190.28  
12/8/2017Anthony G QuinnCEOBuy8,288$4.96$41,108.4832,009  
12/6/2017Anthony G QuinnCEOBuy4,888$4.92$24,048.9632,009  
12/5/2017Charles N York IICFOBuy25,959$4.48$116,296.3210,828  
12/4/2017Anthony G QuinnDirectorBuy7,956$4.98$39,620.8814,100  
12/1/2017Anthony G QuinnDirectorBuy4,100$4.53$18,573.0014,100  
12/1/2017Charles N York IICFOBuy6,500$4.59$29,835.0010,828  
2/21/2017Orbimed Advisors LlcMajor ShareholderBuy109,300$5.16$563,988.00  
4/12/2016Anthony QuinnDirectorBuy10,000$10.00$100,000.0010,000  
4/12/2016Bioventures Ltd NovartisMajor ShareholderBuy300,000$10.00$3,000,000.00  
(Data available from 1/1/2013 forward)

Aeglea BioTherapeutics (NASDAQ:AGLE) Insider Trade Frequently Asked Questions

Who is on Aeglea BioTherapeutics's Insider Roster?

The list of insiders at Aeglea BioTherapeutics includes Anthony G Quinn, and Jonathan Alspaugh.Learn more on AGLE's insiders

What percentage of Aeglea BioTherapeutics stock is owned by insiders?

3.80% of Aeglea BioTherapeutics stock is owned by insiders. Learn more on AGLE's insider holdings

Which Aeglea BioTherapeutics insiders have been buying company stock?

The following insiders have purchased Aeglea BioTherapeutics stock in the last 24 months: Anthony G. Quinn ($783,750.00), and Jonathan Alspaugh ($110,682.60).

How much insider buying is happening at Aeglea BioTherapeutics?

Insiders have purchased a total of 181,980 Aeglea BioTherapeutics shares in the last 24 months for a total of $894,432.60 bought.

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.